Articles Vol. 67 No. VTT

RENOPROTECTIVE EFFECTS OF SGLT2 INHIBITION AND FINERENONE IN TYPE 2 DIABETES: A NARRATIVE REVIEW

Bui Yen Nhi1,2, Nguyen Kim Vuong3,4
1 Vo Truong Toan University
2 Trường Đại Học Võ Trường Toản
3 Vo Truong Toan University Hospital
4 Bệnh Viện Đại Học Võ Trường Toản
0 Views
0 Downloads
Abstract

Objective: To synthesize up-to-date evidence on kidney protection with sodium–glucose cotransporter 2 (SGLT2) inhibitors and the nonsteroidal mineralocorticoid receptor antagonist finerenone in adults with type 2 diabetes (T2D).

Methods: We narratively reviewed randomized controlled trials and practice guidelines published from 2019 to 2025, prioritizing CREDENCE, DAPA-CKD, EMPA-KIDNEY, FIDELIO-DKD, FIGARO-DKD, and ADA/KDIGO recommendations. Outcomes included chronic kidney disease (CKD) progression, kidney failure, albuminuria, and cardiovascular events.

Results: Across diverse CKD phenotypes, SGLT2 inhibitors slowed decline in estimated glomerular filtration rate, reduced composite renal outcomes, and lowered heart failure events, with benefits observed irrespective of baseline atherosclerotic cardiovascular disease. Finerenone, when added to optimized renin–angiotensin system blockade, reduced CKD progression and cardiovascular events in albuminuric T2D-CKD. Current guidelines recommend initiating SGLT2 inhibitors in most patients with T2D and an eGFR ≥20 mL/min/1.73 m². Finerenone should be considered when albuminuria persists despite optimized care and when serum potassium can be monitored.

Conclusions: SGLT2 inhibition provides the therapeutic foundation for renoprotection in T2D-CKD, while finerenone offers complementary anti-inflammatory and antifibrotic benefits. A stepwise, guideline-concordant strategy can slow CKD progression and reduce cardiovascular risk with an acceptable safety profile.

References
[1]
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine. 2019;380(24):2295–2306. Google Scholar
[2]
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2020;383(15):1436–1446. Google Scholar
[3]
EMPA-KIDNEY Collaborative Group; Herrington WG, et al. Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2023;388:117–127. Google Scholar
[4]
Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (FIDELIO-DKD). New England Journal of Medicine. 2020;383:2219–2229. Google Scholar
[5]
Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes (FIGARO-DKD). New England Journal of Medicine. 2021;385:2252–2263. Google Scholar
[6]
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International. 2022;102(5S). Google Scholar
[7]
American Diabetes Association. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl.1):S239–S263. Google Scholar
[8]
Herrington WG, et al. Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY extension). New England Journal of Medicine. 2024;391. Google Scholar
[9]
Nephropathy Trialists. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. New England Journal of Medicine. 2025;392. Google Scholar